NCT03564340 2026-05-08Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersRegeneron PharmaceuticalsPhase 1/2 Recruiting890 enrolled